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ABSTRACT
Objective
To identify opportunities where pharmacists could intervene and justify the
benefits of outpatient clinical pharmacy services through a CDTM protocol within
Gallahue Mental Health Center by assessing current antipsychotic monitoring
Methods
A retrospective chart review was performed of patients visiting an outpatient
psychiatric clinic over 14 months. A review was also completed of patients
followed at two primary care clinics within Community Health Network. Patients
were at least 18 years old and had at least one active antipsychotic prescription.
A standardized data collection sheet was used to document monitoring frequency
and appropriateness

as recommended by the 2004 American Diabetes

Association consensus statement. Demographic information was also collected.
Results
Of those primarily followed in Gallahue, only 1% had any documented fasting
blood glucose or lipid panel, 23% had any documented blood pressure, and 53%
had any documented weight. This differed greatly from the primary care clinics'
results of 63%, 100%, and 92%, respectively. The majority of providers did not
adequately document reasons for not performing recommended monitoring.
Conclusion
Substantial discrepancies exist between current and guideline-recommended
monitoring practices of patients on antipsychotics, thereby supporting CDTM
between clinical pharmacy specialists and providers as a possible solution to
improve evidence-based

patient care.
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INTRODUCTION
Schizophrenia,

Antipsychotic

Medications, and Beyond

Of the various afflictions to the human body, psychiatric disorders, namely
schizophrenia,

have eluded a clear defining and thereby understanding of

etiology. The term "schizophrenia" was first introduced to the medical community
by Swiss psychiatrist Eugen Bleuler in 1908, a break from a long-standing
diagnosis of "dementia praecox" that gave all patients with psychosis an
unavoidably poor proqnosis.' Schizophrenia as a disease state, therefore, rose
from opposing opinions on how diagnosed patients would progress rather than
from an exact matter of pathophysiology. Such grey area in psychiatry persists
today, with the fifth edition of the Diagnostic and Statistical Manual of Mental
Disorders (OSM-5) placing schizophrenia as a diagnosis on the continuous
schizophrenia spactrum.f Understanding a patient's psychosis is relative at best,
relying heavily on the process of differential diagnosis.
That elusive understanding of psychosis has come in closer reach with the
advent of antipsychotic agents. The first typical antipsychotic chlorpromazine was
introduced in the early 1950s, followed by the first atypical antipsychotic
clozapine in the late 1960s and over 60 other antipsychotic agents at some point
in time worldwide." Biomedical researchers have suggested excess
dopaminergic transmission as the cause for diseases like schizophrenia, since all
antipsychotic drugs to date have some degree of dopamine blockade." This is
likely not the complete story, however: none of these agents fully alleviate all
symptoms associated with schizophrenia, and some atypical antipsychotic
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agents have seemingly been just as or even more effective for disease states
outside of the schizophrenia spectrum, such as bipolar disorder and major
depressive dlsorder.I'" No matter the lack of clarity, though, antipsychotic
medications remain an important component of therapy for patients with
psychiatric disorders.
Antipsychotic

Medications' Inherent Risks

While demonstrating efficacy in controlling psychiatric disorders,
antipsychotic medications are not without significant short- and long-term risks.
Typical, or "first-generation," antipsychotic agents are shown to cause a
significant degree of extrapyramidal side effects (EPS) and other neurologic
adverse drug reactions, thought to be associated with their potent blockade of 02
receptors that induces a neurochemical imbalance as seen in Parkinson'S
disease.i:" Atypical, or "second-generation,"

antipsychotic agents are believed to

cause a lesser degree of EPS, though their long-term use is associated with an
increased risk of metabolic syndrome.9•1o The American Heart Association and
National Heart, Lung, and Blood Institute have defined metabolic syndrome as at
least three of the following risk factors: large waistline (~40" in men and ~35" in
women); high triglyceride level (~150 mg/dL); low HOL cholesterol level «40
mg/dL in men and <50 mg/dL in women); high blood pressure (~130 mmHg
systolic or ~85 mmHg diastolic); or high fasting blood sugar (~1 00 mq/dl.)." The
causal relationship between atypical antipsychotics and metabolic syndrome is
unclear and likely multifactorial. Proposed mechanisms of this relationship have
included impaired tissue glucose uptake due to 5-HT2A receptor antagonism;
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impaired insulin gene expression by pancreatic beta-cells due to inhibition or
induction of various enzymes; and impaired activity of leptin, a hormone involved
in appetite control, due to 5-HT2c receptor antaqonism."
Psychiatric and Cardiovascular Disease
To build upon the risks associated with atypical antipsychotic use, a
review of the literature suggests that patients with psychiatric disorders are
predisposed to cardiovascular disease. A 2011 selective review for
epidemiological,

morbidity, and mortality data on the relationship between

psychiatric disorders and physical illnesses concluded that individuals with
severe mental illness were more likely to have hypertension, dyslipidemia, or
diabetes mellitus; to be overweight or obese; and to smoke."

While lifestyle

habits and access to primary care are surely contributing factors, this overarching
trend across various populations may indicate a link to the disease process itself.
A Call for Closer Clinical Monitoring
A national probability sample survey of office-based physician practices to
evaluate antipsychotic use trends in the United States found that antipsychoticrelated office visits increased from 4.6 million in 1998 to 8.6 million in 2002, a
change of 187%.14 With the continued discovery of new antipsychotic drugs and
their expanding use in unique disease states since 2002, practice guidelines and
guidance documents were developed to help clinicians monitor the safety of the
increased number of patients using these agents.
The 2002 Mount Sinai Conference, an assembly of expert psychiatryfocused research groups, created a summary document that included
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recommended

monitoring frequencies for different types of antipsychotic

medications. The document's recommendations

included annual monitoring, at

minimum, for tardive dyskinesia and EPS using a standardized tool such as the
Abnormal Involuntary Movement Scale (AIMS).15 A copy of this scale, which
includes standardized monitoring for EPS, can be found in Appendix A.
As more literature came to light involving the close association between
atypical anti psychotics and cardiovascular disease, the American Diabetes
Association (ADA), along with the American Psychiatric Association, the
American Association of Clinical Endocrinologists, and the North American
Association for the Study of Obesity, published a consensus statement
conveying recommendations for atypical antipsychotic monitoring practices.
Monitoring measures recommended in this document included personal and
family history of metabolic syndrome risk factors, weight, waist circumference,
blood pressure, fasting plasma glucose, and fasting lipid profile."

These

measures would allow the psychiatrist or other provider to initiate appropriate
therapy for the comorbidity, or refer the patient to another health care
professional knowledgeable about the disease state. A copy of this monitoring
protocol for atypical antipsychotics is found in Appendix B.
Continuing Gaps in Patient Care
Although published over a decade ago, available research suggests that
actual clinical practices have been slow to adopt ideal monitoring
recommendations.

A 2012 systematic meta-analysis of both inpatient and

outpatient studies analyzing routine screening practices in patients taking
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anti psychotics found that blood pressure and triglycerides were the only
parameters measured at a rate above 50%; the nine studies that directly
examined monitoring before and after guidelines implementation only found a
statistically significant improvement in fasting blood glucose testing at 15.4% (RR
1.47,95%

CI1.13-1.9,

p=0.005).17 More so, it has been estimated that at least

20 minutes are necessary for metabolic syndrome screening in addition to a
standard psychiatric consuttatton."

The anecdotal estimate for length of a follow-

up visit within Gallahue Mental Health Center is 15 minutes. While psychiatrists
and other behavioral health providers have the literature to understand these
medication-related

issues, they may not have enough time in an individual's

follow-up visit to address such monitoring.
Collaborative

Drug Therapy Management

As pharmacists have gained more experience in specialty areas of
medicine, clinical practice has evolved to allow them greater autonomy to affect
patient care positively. The American College of Clinical Pharmacy (ACCP)
published a position statement in 2003 regarding collaborative drug therapy
management (COTM), defined as the following:
"a collaborative practice agreement between one or more
pharmacists working within the context of a defined protocol [that]
are permitted to assume professional responsibility for performing
patient assessments; ordering drug therapy-related laboratory
tests; administering drugs; and selecting, initiating, monitoring,
continuing, and adjusting drug reqlmens""
Such work has grown rapidly throughout the past decade, with 47 states
(including Indiana) and the District of Columbia allowing some degree of COTM
as of early 2013.20 The majority of these agreements have been in the practice
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areas of infectious disease, anticoagulation, parenteral nutrition, pain
management, cardiovascular health (e.g. heart failure, dyslipidemia,
hypertension), and diabetes mellitus."
Psychiatric Pharmacists' Qualifications
Clinical pharmacy specialists have the opportunity to target psychiatry as
their field of expertise through additional training beyond a Doctor of Pharmacy
degree. The American Society of Health-System Pharmacists (ASHP) offers
accredited residency programs in psychiatric pharmacy, which seek to develop
multidisciplinary team skills and improve pharmacotherapy
behavioral health disorders."

knowledge related to

Pharmacy fellowships are also available for

additional training, though only one psychiatry-focused

fellowship has been

accredited by ACCP.23 The Board of Pharmacy Specialties (BPS), an
autonomous division of the American Pharmacists Association (APhA), provides
pharmacists with the opportunity to become board-certified in psychiatric
pharmacy, demonstrating their ability to assess patients, monitor drug responses,
recognize drug-induced problems, and recommend appropriate treatment
plans." In addition to formalized training and certifications, the College of
Psychiatric and Neurologic Pharmacists (CPNP), a professional pharmacy
organization, offers a platform for clinical pharmacy specialists to consult
colleagues on unique challenges that arise in their practices."

Through

residency or fellowship training, board certification, and the support of
professional organizations, psychiatric pharmacists are well-qualified to make
significant contributions to the ongoing, chronic care of their patients.
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Psychiatric

Pharmacists

within COTM

While plenty of literature is available supporting CDTM's impact on patient
care outcomes for cardiovascular and endocrine disease states, information
regarding CDTM practices in psychiatry-specific populations is limited. Some of
the published literature has involved safety-net clinics and indigent populations,
cases that are hard to generalize to other care centers.26,27 Other pharmacist-run
psychiatric services have been started within the Department of Veterans Affairs,
a health system that is difficult to extrapolate to private sector practices due to its
28

long-standing history of giving expanded prescribing rights to pharmacists.

,29

Furthermore, almost all psychiatric pharmacists serving these clinics were funded
at least in part by a university, making the setup of such clinics less financially
feasible in a non-teaching health system.18,26,27,29,30

A meta-analysis of the

literature from 1972 to 2003 found significant improvements in the use of
psychotropic drugs when clinical pharmacists acted as treatment consultants and
patient educators, despite the lack of large-scale studies."

Until such studies are

completed, site-specific studies are critical in proving the value of psychiatric
pharmacists in mental health clinics.
Community

Health Network

Community Health Network is a non-profit, non-teaching health system
with more than 200 patient care sites throughout central Indiana.f The health
system also acts as the largest provider of behavioral health for central Indiana,
with more than 19,000 outpatient client visits each year provided to pediatric,
adult, and geriatric populations.f

Gallahue Community Support Services
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(GCSS), one of several outpatient psychiatric clinics within the health system's
Gallahue Mental Health Center, was the primary location involved in this study.
Eastside Medical Center and Jane Pauley Primary Care Clinic, the secondary
locations involved in this study, are outpatient primary care clinics for the health
system. These primary care clinics already have clinical pharmacists on staff
acting within collaborative practice agreements; however, they are similar to
GCSS by their geographical location and high proportion of Medicaid-insured
patients, allowing for appropriate comparison in this study.
Project Scope
A clinical pharmacy specialist in psychiatry currently spends approximately
20 hours each week at GCSS, informally seeing patients in an effort to improve
their long-term medication monitoring. A previous pharmacy-driven

study within

Community Health Network worked on establishing psychiatrist-pharmacist
relationships and determining an appropriate means of billing for the psychiatric
pharmacist."

This study will build upon that foundation, adding a clinical backing

to these pharmacoeconomic

dimensions. The presented thesis focuses on the

information obtained from the retrosp~ctive chart review phase of this overall
initiative and was completed to fulfill the Doctor of Pharmacy degree graduation
requirements for the author.
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OBJECTIVES
The primary objective of this study was to demonstrate the need for
pharmacy staff and to justify the benefits of implementing outpatient clinical
pharmacy services through a CDTM protocol at Gallahue Mental Health Center
in Indianapolis, Indiana. A parallel objective was to collect, analyze, and present
data on current antipsychotic monitoring practices at an outpatient psychiatric
clinic, specifically in relationship to evidence-based guidelines and to monitoring
practices at two primary care clinics within Community Health Network.

HYPOTHESIS
Considering the literature on current antipsychotic monitoring trends, it
was hypothesized that monitoring practices at GCSS would fall short of those
recommended by the 2002 Mount Sinai Conference and the 2004 ADA
consensus statement. It was also predicted that more frequent monitoring would
be documented for those patients primarily followed at a primary care clinic,
since these providers are more commonly focused on hypertension,
dyslipidemia, and diabetes mellitus.

METHODS
Project Timeline
The study was approved by the Community Health Network Institutional
Review Board in October 2014 in conformity with the Declaration of Helsinki's
research prtnclpies." Additionally, as required by Butler University and
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Community Health Network policies, the Collaborative Institutional Training
Initiative (CITI) Program covering human subject research was completed prior to
starting the oroject."

Data collection began in early November 2014 and

concluded in early January 2015. Statistical analysis of the data took place
throughout February and March. Study findings were presented in April at the
Butler University Undergraduate Research Conference.
Inclusion and Exclusion Criteria
Patients were included in the study if they were at least 18 years old and
had at least one active prescription for an antipsychotic medication. Patients
were excluded if they did not meet the age requirement or did not attend at least
one follow-up visit at their clinic site.
Data Source
A possible subject list was created by pulling the medical record number
(MRN) from the Epic® electronic medical record system of patients who visited
one of the study sites from November 1, 2012, to December 31, 2013, and were
prescribed a medication in the therapy class of "psychotherapeutic

drugs." The

start date was chosen based on when Epic® was fully implemented within the
Community Health Network sites of interest, and the 14-month timespan was
chosen to capture one year's worth of baseline and follow-up visits for included
subjects. The generated list was narrowed to include only those patients
prescribed an antipsychotic medication. The data collection phase of the study
utilized this revised list.
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Data Collection

Sheet

A data collection sheet was developed prior to the study's beginning that
incorporated monitoring parameters from both the 2002 Mount Sinai Conference
and the 2004 ADA consensus statement. In addition to demographic information,
data on currently and previously prescribed antipsychotics, indication, other
active medications, comorbidities, social history, and time between clinic visits
was gathered to get a better account of overall clinic practices. Images of this
data collection sheet can be found in Appendix C.
Statistical

Analysis

The primary means of study analysis for baseline subject characteristics
and other nominal data was descriptive statistics. Due to the small volume of
documented values, information on monitoring for tardive dyskinesia, EPS, and
metabolic syndrome was converted to nominal data where feasible for ease of
analysis. Most of the demographic information was analyzed for significant
differences with a Chi-square test or a Fisher's exact test, with the exception of
an ANOVA test for ethnicity, an ANOVA test for antipsychotic indication, and an
unpaired t-test for age. In addition, a Chi-square test or Fisher's exact test
analyzed number of documented visits, specific antipsychotic use, and whether
or not monitoring was completed at the various clinic sites. A p-value < 0.05 was
set as the threshold for statistical significance for all of these tests.
For quantitative monitoring results, mean values were calculated for
weight, systolic blood pressure, diastolic blood pressure, fasting blood glucose,
total cholesterol, triglycerides, HDL cholesterol, and LDL cholesterol. An unpaired
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t-test was used to compare the calculated means of GCSS and of the two
primary care clinics, with a p-value < 0.05 set as the threshold for statistical
significance. Statistical tests were not run for tardive dyskinesia and EPS
monitoring due to a lack of documented results from the two primary care clinics.
All statistical tests mentioned above were run using the Microsoft Excel
2010 Analysis ToolPak Add-In.

RESULTS
Study Size and Demographics
Of the patients that were prescribed a "psychotherapeutic

drug," two-

hundred fifty individuals were receiving an antipsychotic medication. Following
the completion of data collection, two-hundred four subjects were found to be
eligible for inclusion in study analysis: 88% (n=180) from GCSS and 12% (n=24)
from the two primary care clinics. A diagram detailing the exact number of
subjects from each clinic included and excluded is shown in Appendix D.
Most of the GCSS subjects were female at 54% (n=98), with the same
percentage of females present in the primary care clinics (n=13). The majority of
GCSS subjects were Caucasian and black at 52% (n=93) and 45% (n=81),
respectively. This ethnicity trend was inverted at the primary care clinics, with
42% (n=1 0) being Caucasian and 54% (n=13) being black. The mean age for
GCSS subjects was 44.9 ± 12.9 years, which was lower than the primary care
clinics' mean age of 49.1 ± 19.5 years. Hypertension, hyperlipidemia, and obesity
were the most common comorbidities in all subject groups, with obesity as the
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most frequently reported in 52% (n=93) of GCSS subjects and 54% (n=13) of
primary care clinic subjects. Hyperlipidemia was the only comorbidity with a
statistically significant difference, being found in 24% (n=43) of GCSS subjects
and 58% (n=14) of primary care clinic subjects (p=0.0004). Hypertension
(p<0.05), diabetes mellitus (p=O.0084), and CAD (p=0.0066) were significantly
more present in the family histories of GCSS subjects. Tobacco, alcohol, and
illicit drug use were frequent, with 44% (n=79) of GCSS subjects and 33% (n=8)
of primary care clinic subjects having documented tobacco use.
While not statistically significant, some perhaps clinically significant
differences were found between study groups concerning antipsychotic indication
and use history. The most common indications for antipsychotic use at GCSS
were schizophrenia at 49% (n=89) and schizoaffective disorder at 23% (n=42), in
contrast to rates of 13% (n=3) and 0% respectively at the primary care clinics.
The most common indication at the primary care clinics was major depressive
disorder (MDD) at 29% (n=7). In addition, 27% (n=48) of GCSS subjects had
some documented history of antipsychotic use, whereas only 8% (n=2) of
primary care clinic subjects had a documented history. More details about these
differences and demographic information are captured in Table 1.
Clinic Visits by Subjects
GCSS subjects had more frequent follow-up during the study timeframe
than those at the primary care clinics. Only 21 % (n=5) of primary care clinic
subjects visited their provider more than five instances in the 14-month period, in
contrast to 59% (n=1 06) of GCSS subjects. The average length of time between
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clinic visits was 7.1 ± 4.13 weeks for GCSS subjects, while the average time for
the primary care clinic subjects was 14.7 ± 12.S weeks (p<O.OS).
An inverse relationship was seen between study site and how often the
scheduling of follow-up clinic visits was documented in clinic notes. GCSS
providers only documented about follow-up in S8% (n=662/11S0) of total subject
visits, notably lower than the 88% (n=99/112) of instances seen with the primary
care providers (p<O.OS). Table 2 shows specific information about clinic visits for
each of the study groups.
Antipsychotic

Medication Use

Atypical anti psychotics were used more frequently as a class in this study
than their older, typical antipsychotic counterparts. Of the total instances of
unique antipsychotic

use for a given study site's subjects, atypical anti psychotics

were prescribed in 82% (n=214/262) of GCSS instances and 88% (n=22/2S) of
primary care clinic instances. The only atypical antipsychotics prescribed to
subjects at GCSS and both primary care clinics were quetiapine at 22% (n=40)
and 46% (n=11), respectively, and aripiprazole at 19% (n=34) and 21 % (n=S),
While typical anti psychotics were prescribed in both study groups, the large
majority were used at GCSS, being prescribed in 18% (n=48/262) of GCSS
instances and 12% (n=3/2S) of primary care clinic instances. The most commonly
prescribed of the typical antipsychotics was haloperidol for 17% (n=3S) of study
subjects overall.
GCSS providers had unique prescribing trends compared to their primary
care counterparts.

No subjects at the primary care clinics received a long-acting
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antipsychotic injection as part of their medication regimen, compared to 44%
(n=79) of subjects at the outpatient psychiatric clinic (p<0.05). Twenty-nine
percent (n=53) of GCSS subjects were prescribed multiple anti psychotics at one
time, compared to only 4% (n=1) of primary care clinic subjects (p=0.0061).
Twenty-seven

percent (n=48) of GCSS subjects were started on a new

antipsychotic at some point during the study timeframe, while 46% (n=11) of
subjects were at the primary care clinics. A detailed breakdown of antipsychotic
use by study group is shown in Table 3.
Tardive Dyskinesia and Extrapyramidal Side Effects Monitoring
No standardized scales were used to monitor for EPS at any site, and
tardive dyskinesia monitoring with AIMS was only performed at 2.8%
(n=32/1150)

of GCSS subject visits. Of these 32 structured assessments, thirty

AIMS scores were "0" and two AIMS scores were "1." Specific items were often
unreported, with providers usually documenting a total AIMS score in their clinic
note rather than using the AIMS scoring system available in EpiC®.
Metabolic Syndrome Monitoring
Monitoring of weight, blood pressure, fasting blood glucose, and fasting
lipid panels was significantly better at the two primary care clinics than the
outpatient psychiatric clinic. These respective measures were checked at 96%,
100%, 30%, and 25% of study visits at the primary care clinics, contrasting with
respective frequencies of 14%, 6%, 0.2%, and 0.3% of study visits at GCSS
(p<0.05). Family history monitoring took place at 57% of primary care clinic visits
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and 53.7% of GCSS visits, though this was not a statistically significant
difference. An exact count of monitoring instances is listed in Table 4.
With the limited amount of continuous data obtained, the only statistically
significant differences between GCSS and the two primary care clinics were
weight and blood pressure. The mean weights for these study groups were 94.4
kilograms and 168.1 kilograms, respectively (p<0.05). The mean systolic blood
pressures were 130.5 mmHg and 121.6 mmHg (p=0.00064), and the mean
diastolic blood pressures were 84 mmHg and 74 mmHg (p<0.05). While
statistically insignificant, a large difference of means was found in measured
triglycerides on fasting lipid panels, being 193.3 mg/dL for GCSS and 126.8
mg/dL for the primary care clinics (p=0.11422). Waist circumference was not
measured or documented at any study visit. A complete analysis of continuous
data is provided in Table 5.

DISCUSSION
Outpatient Psychiatric Clinic Practices
According to the 2002 Mount Sinai Conference, patients on atypical
anti psychotics should be monitored annually for tardive dyskinesia and EPS
despite their lower risk of developing these symptoms as compared to patients
on typical antlpsychotlcs."

Only 27 of the 180 subjects followed during this 14-

month period at GCSS had an AIMS score documented, suggesting possible
gaps in tardive dyskinesia and EPS monitoring.
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It has been deduced in the literature that atypical antipsychotic monitoring
for metabolic syndrome has not improved substantially since the 2004 ADA
consensus statement. A review of administrative claims data from major health
insurance plans in the United States from 2001 to 2006 suggested that 75% of
patients on anti psychotics received no baseline glucose testing and 90%
received no baseline lipid panel by the end of 2005.37 According to electronic
medical record documentation, rates within Gallahue Mental Health Center were
seemingly worse than these reports.
Furthermore, nearly one-third of subjects at this clinic experienced
antipsychotic

polypharmacy, increasing the risk of side effects from these

medications.

Documentation providing medical necessity for the use of multiple

anti psychotics was not provided in the medical records for most subjects.
Primary Care Clinic Practices
None of the subjects followed at the primary care clinics had documented
monitoring for tardive dyskinesia or EPS. This suggested lack of monitoring could
reflect a lesser appreciation in non-psychiatry settings for the neurologic risks
associated with antipsychotic medications.

In regards to metabolic syndrome risk factor monitoring, the primary care
clinics were highly effective at monitoring weight and blood pressure, checking
these values at almost every clinic visit. Frequency was lower for fasting blood
glucose and lipid panels, though this was significantly higher than monitoring
practices at the outpatient psychiatric clinic. However, such practices could
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reflect the primary care treatment of cardiovascular and endocrine disease states
rather than conscious monitoring of the long-term effects of antipsychotic use.
Differences in Monitoring Results
It is unclear why such a drastic difference in measured weights existed
between GCSS and the primary care clinics, particularly since no major outliers
were present and comorbidity differences at baseline were insignificant.
Regardless of statistical significance, this information about weight should be
interpreted with caution, since height data was not collected to allow for body
mass index (8MI) calculations of patients. Waist circumference is a monitoring
parameter recommended by the 2004 ADA consensus statement, since
abdominal obesity and body fat distribution changes have been possibly linked to
insulin resistance and dysllpldemla."

No waist circumference measurements

were documented at GCSS and the primary care clinics, and a weight outside of
context is not as helpful in preventative monitoring for metabolic syndrome.
The significant difference in measured blood pressures seems more
logical, since the primary care clinics completed this monitoring at every followup visit. GCSS subjects' mean blood pressure values of 130.5 mmHg systolic
and 84 mmHg diastolic were also around the metabolic syndrome risk factor
threshold of ~130/85 rnrnl-lq." This finding could suggest better control of
comorbid hypertension by primary care providers, and it could also support the
theory that individuals with schizophrenia spectrum disorders are at a greater
baseline risk for cardiovascular disease."
No strong inference can be drawn from fasting blood glucose and fasting
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lipid panel, since these two labs combined were only completed in five instances
at GCSS altogether. While one would not expect these more extensive labs at
every clinic visit, fasting blood glucose should be checked at least annually
according to the 2004 ADA consensus statement, meaning this parameter should
have been documented for the majority of subjects over the 14-month period."
A Place for Pharmacy Expertise
Along with being well-qualified as medication management experts by
their extensive education and training, pharmacists are ideal health care
professionals for identifying how to act upon monitoring results appropriately. In
previously described CDTM practices within psychiatry, the clinical pharmacist
acted as the connection between the many other health care team members.
Following an assessment, dosage changes, and medication counseling, a
psychiatric pharmacist at a fluphenazine decanoate clinic was able to consult the
28

psychiatrist, clinic nurse, or social workers as required for the patient's needs.
Clinical pharmacists'

recommendations were also well-received by providers in

the available literature, being accepted >90% of instances at an outpatient
· . 2627
psychiatric pharmacy clinic for indigent populations and at a safety-net c Itrue. '
As health care continues to advance its understanding of the pathophysiology of
psychiatric disease states such as schizophrenia, antipsychotic use will likely
become even more of a therapeutic cornerstone. Having a psychiatric pharmacist
closely involved with the care of clinic patients through a CDTM protocol will
ensure that these medications are utilized safely and effectively.
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Study Limitations
First, it is possible that monitoring rates were higher than study findings at
all study sites due to a lack of standardized documentation in clinic notes. While
psychiatrists at GCSS were likely checking for signs of tardive dyskinesia and
EPS at most clinic visits, the lack of AIMS score documentation did not capture
these instances in the study. Providers also may have reviewed labs performed
at other outpatient clinics rather than completing them in office, though this was
not consistently documented for most subjects.
In addition, the study author was not always able to identify the precise
initiation date of a subject's antipsychotic medication, making it difficult to assess
adherence to monitoring recommendations of the ADA from baseline onward as
shown in Appendix B. Because the Epic® electronic medical record system went
online just prior to the starting point of this study, it was hard to locate and
interpret clinic history from the previous system. While the monitoring parameters
in the ADA consensus statement are based upon number of weeks since
initiating an antipsychotic medication, the study author opted to look for
parameters at every follow-up visit due to the large amount of unknown start
dates for subjects' anti psychotics.
Finally, small sample sizes in the chosen primary care clinics limited the
power of this study to detect actual practice differences. The initially generated
list of patients receiving a "psychotherapeutic

drug" within Community Health

Network likely missed a substantial number of possible subjects, perhaps also
due to the relatively recent implementation of Epic® in the health system.
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CONCLUSION
The objective of this study was to demonstrate the need for a CDTM
protocol within Gallahue Mental Health Center that would allow a clinical
pharmacist to bring antipsychotic monitoring practices into closer alignment with
the most recent guidelines from the ADA, other professional organizations, and
expert panels. Analyzing the clinic visits of patients on antipsychotics over a 14month period showed significant gaps in both performing and documenting such
interventions. The results of this study, in conjunction with current literature on
the collaboration of psychiatric pharmacists in outpatient clinics, could justify
CDTM implementation

as a feasible means of strengthening the holistic care of

those receiving anti psychotics for behavioral health disorders.
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APPENDICES
Appendix

A (AIMS+EPS)

AIMS-PLUS EPS
(ABNORMAL INVOLUNTARY MOVEMENT SCALE-PLUS
EXTRAPYRAMIDAL
SIDE EFFECTS SCALE)

Instructlons:

Rate highest severity obsal\leo. Rata movements that occur upon acuvaucn
one less than those obSel\leO spontaneouslY·
O. None: 1 .. Minimal. may be eXUEr:1enonnat: 2 = Mild: 3 .. Moderate: 4 .. Severe

Cede:

(circle the appropriate rallng beloWI.

TARDIVE

DYSKINESIA

(Do not Include Tremors)

1. Muscles of facial expression
e.a .• movements

of foren'fJad. eyebrows.

include

blinking.

frowning.

per/oroital

eree

Jaw

e.g .• biting.

-------------------------·
clencnmg. cl1ewmg. mourn oaenrng.

4. Tonguo

latera

;':emenr

----

5. Upper extremities

(arms. ·....
rists. -anns. fingers, ---------------

Include cnoretc movements (i.e .. rapid. objectIvelY p .. ··:;;"lIess. Irregular.
spontaneous).
athetoid movemenrs (i.e .• slow, ineqc.«: zomotex. setpenune)
6. Lower extremities
(legs, knees. ankles. toes)
e.g .• irregular lateral knee movement. irregular
7. Trunk movements (neck. shoulders. nips)
e.q.. irregular rocking. twisting, squirmmg.

foot or ~eel movements

-:-:-----.-------or pelvic gyrations

SIDE EFFECTS

1. Dystonia
----e.g., persistent
spasm usually of the ':.d~~ .: ;8. necx or (JaCK muscles
(1.;",'5 results in persistent abnormal OOSltlc.-I~g of one or more extremities
or :1 ttie face. neck. or trunk)
2. Parklilsonism
-:- __
o.g .• oraaykinesl8
resting

tremor.

_:_-------------~---------------------(deCreBsea movement). :;-;uffling

3. Akathisia
e.a .. resttessness.

paclna,

e.q.

rOCKInC. mantiltv to Sit sU11

-.'
increesea

mUSCle tone with contmuous

cog-wheel
rigidity
tremor
,).9 .. slow. rhythmiC.

present

mawr

ro

movements

movements

often associated

ana oaresthes/Bs

4

0

2 3

4

0
0

2 3 4
2 3 .:

o , 2

2 3

0

o

3 4
4

Total:

1

234

o ,

234

o

2 3 4

o

2 3 4

o

2 3 4

o

234

movement.

at rest (pill rolling!

6. Akinesia ~-,--:-------:------:--:--:--:----------Decreased

resistance

----.-_:_7-------------

5. Parkinson

spontaneous

osssive

2 3

galt. maSKlike facies.

droOling

4. Rigidity

0

iD

,~

EXTRAPYRAMIDAL

234

zneexs:

smIling. gnmacmg

2. Lips and perioral area ------------e.g .• puckermg.
pouting, sr.;acking

3.

o ,

with weakness,

oecreeseo
EPS Total:

_

COMMENTS:

Examiner:

Date:
_.

I
-----
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Appendix B (2004 ADA Consensus Recommended Monitoring)
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Appendix C (Data Collection Sheet)

o
o
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Appendix D (Subject Inclusion and Exclusion)

Individuals found on
antipsychotic medication
within CHN
N=2S0

I
Gallahue Mental
Health Center
N=19S
Gallahue Community

Primary Care Clinics
N=SS
Eastside (N=40), Jane Pauley (N=15)

Support Services

15 Patients Excluded:

31 Patients Excluded:
Eastside (N=21), Jane Pauley (N=10)

No documented visit (N=8)

No documented visit (N=2)

No follow-up visit (N=4)

No follow-up visit (N=14)

Patient < 18 years old (N=2)

Patient < 18 years old (N=12)

Patient refused antipsychotic (N=l)

Antipsychotic not renewed (N=3)

Gallahue Mental
Health Center subjects
included in study

Primary Care Clinics
subjects included in study

N=180

N=24

Eastside (N=19), Jane Pauley (N=5)
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TABLES
Table 1 (Subject Demographics)

Gallahue Mental
Health Center
N=180 ,

Primary Care
Clinics
N=24

0.9795

0.16383

0.085
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-.-.------- ... --.---.--~----

Table 2 (Clinic Visit Information)

"

Gallahue Mental
Health Center

Follow-Up Clinic
Visit Scheduled
(of total visits)

7.1 (50=4.13)

14.7 (50=12.51)

57.6% (662/1150)

88.4% (991112)
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Table 3 (Antipsychotic

Medication Use)

Gallahue Mental
Health Center

Use of LongActin
ctions
Antipsychotic
Polypharmacy
Subjects
Starti
New AP

1
79 (43.9%)
53 (29.4%)

1 (4.2%)

0.0061

48 (26.7%)

11 (45.8%)

0.0588
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Table 4 (Completion of Monitoring at Clinic Visits)

Gallahue Mental
Health Center*

YES

NO

YES

NO

Family History

617

533

64

48

Weight

163

987

107

5

2.3x1

Blood Pressure

65

1085

112

112

3.27x1

Fasting Blood
Glucose
Fasting Lipid
Panel

2

1148

33

79

8.14x1

3

1147

28

84

4.37x1

0.4792

*1150 individual clinic visits recorded at the Gallahue Mental Health Center clinic
individual clinic visits recorded at the two primary care clinics

+ 112
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Table 5 (Metabolic Syndrome Monitoring Results)

Gallahue Mental
Health Center
Mean (Standard
94.4

.34)

Weight (
Blood
Pressure
Systolic BP

130.5 (21.78)

121.6 (12.67)

0.00064

Diastolic BP

84 (14.9)

74(11)

7.68x10-

Fasting Blood
Glucose

96.5 (12)

120.1 (61)

0.59384

184 (30.27)

181.4 (49.64)

0.93018

Triglycerides

193.3 (27.21)

126.8 (69.28)

0.11422

HDL Cholesterol

36.7 (16.86)

48 (12.47)

0.15637

LDL Cholesterol

109(21.7)

108 (42.57)

0.96973

Fasting Lipid
Panel
Total Cholesterol
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